Liquid Biopsy Market Size, Share, Trends | Industry Report 2022

The key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for non-invasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.

According to the new market research Liquid Biopsy Market is expected to reach USD 2,047.9 Million by 2022 from an estimated USD 715.7 Million in 2017, at a CAGR of 23.4%.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350

• By circulating biomarkers, circulating tumour cells is expected to account for the largest market share in 2017
• By clinical application, the therapy selection segment is expected to account for the largest market share in 2017
• By application, the cancer segment is expected to account for the largest market share in 2017
• By end user, the reference laboratories segment is expected to account for the largest market share in 2017

By product, the assay kits segment is expected to account for the largest share of the market in 2017
On the basis of product, the liquid biopsy market is broadly segmented into assays kits, instruments, and services. In 2017, the assay kits segment is expected to account for the largest share of this market. The increase in basic research and commercial applications of liquid biopsy, increase in demand for liquid biopsy tests, and the need for reliable and specific assays are expected to drive the market growth.

The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350

North America is expected to dominate the market in 2017
North America is expected to account for the largest share of the liquid biopsy market in 2017, followed by Europe. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of cancer in the US and Canada, technological advancements in liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region.

Wearable Medical Devices Market Growth Factors and Industry Report 2022

Factors such as technological advances in medical devices, increasing penetration of smartphones and growing number of smartphone-based healthcare apps compatible with wearable devices, growing preference for wireless connectivity among healthcare providers, and increasing awareness about physical fitness are driving the growth of this market.

According to research report the wearable medical devices market is expected to reach USD 14.41 billion by 2022 from USD 6.22 billion in 2017, at a CAGR of 18.3%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81753973

Based on application, the wearable medical devices market is segmented into remote patient monitoring, home healthcare, and sports & fitness. The sports and fitness segment is expected to register the highest CAGR during the forecast period. The significant growth of segment is owing to factors such as the increasing focus on physical fitness among people to improve the quality of life and growing trend of tracking health progress.

Based on type, the wearable medical devices market is segmented into activity monitors, smartwatches, smart clothing, and patches. The activity monitors segment is expected register the highest CAGR during the forecast period. The high growth of this segment can be attributed to factors such as the rising adoption of sedentary and unhealthy lifestyles, rising prevalence of lifestyle diseases, and growing awareness of health and fitness.

Based on distribution channel, the wearable medical devices market is segmented into pharmacies, online channel, and hypermarkets. The pharmacies segment is expected to dominate the market during the forecast period. The growth of this segment is mainly attributed to factors such as increasing trend towards self-monitoring and non-invasive monitoring and diagnosis and substantial increase in the supply of wearable devices in pharmacies.

Among the four regional segments covered in the wearable medical devices market—north America, Europe, Asia Pacific, and the Rest of the World (RoW). Geographically, the wearable medical devices market in the Asia Pacific region is expected to register the highest CAGR during the forecast period. Growth in this regional segment is largely driven by the increased spending on healthcare, faster economic growth, presence of a huge population base, and increasing prevalence of diseases in the region. Furthermore, changes in lifestyle and increasing awareness on wellness and fitness are also expected to boost market growth in the region.

Spirometer Market – Business Growth Opportunities | Global Forecast 2023

The report studies the market on the basis of product type, mechanism, application, end user, and region. Market growth is largely driven by the rising global incidence of respiratory diseases, global population, and technological advancements in spirometer devices.

According to research report the global Spirometer Market is expected to reach USD 1,047 million by 2023 from USD 655 million in 2018, at a CAGR of 9.8%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=18015659

The spirometry equipment market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). Asia is expected to register the highest CAGR in the market during the forecast period. The high growth in this region can primarily be attributed to the rising geriatric population, high burden of respiratory diseases such as COPD and asthma, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for cutting-edge technologies, expansion of private-sector hospitals to rural areas in various APAC countries, and the presence of high-growth markets such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore.

By product type, the spirometry equipment market is segmented into consumables & accessories, devices, and software. The consumables & accessories segment accounted for the largest share in 2018. The rising incidence of respiratory diseases and the growing geriatric population are the key factors driving the growth of this product segment.

By end user, the spirometry equipment market is segmented into hospitals, clinical laboratories, home care settings, and industrial settings. Hospitals accounted for the largest share of the spirometry equipment market in 2018 while the home care settings segment is expected to register the highest growth during the forecast period. The growing requirement for personalized lung monitoring is a key factor driving the growth of the spirometry equipment market for home care settings.

Based on application, the spirometry equipment market is segmented into COPD, asthma, and other applications. Among these, the COPD segment accounted for the largest share of the spirometry equipment market in 2018. The large share of this segment is mainly due to the high and growing prevalence of COPD globally and the easy diagnosis of COPD offered by spirometry.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=18015659

Key players in this market can explore the possibilities of expanding to the emerging economies of India and Brazil. These countries are going through a phase of rapid industrialization, leading to increasing pollution levels. This has created a need for monitoring lung conditions regularly, which increases the demand for spirometers.

Minimally Invasive Surgical Instruments Market Size, Share, Trends | Global Forecast 2021

With rising geriatric population, presence of a large patient pool undergoing surgical treatments, growing awareness about modern surgical instruments and techniques, and implementation of various initiatives to reduce the rising healthcare expenditure in Asia-Pacific, the demand for minimally invasive surgical instruments in this region is expected to grow, which in turn will compel the key players to expand their geographical presence in this region.

The market is segmented on the basis of product, application, and end user. By product, the market includes handheld instruments, electrosurgical instruments, inflation systems, guiding devices, auxiliary instruments, and cutter instruments.

Download Free Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=682

According to the new market research report Minimally Invasive Surgical Instruments Market is projected to reach USD 21.47 Billion by 2021 from USD 13.89 Billion in 2016, at a CAGR of 9.1%. Asia-Pacific is expected to grow at the highest rate.

• By product, the market includes handheld instruments, electrosurgical instruments, inflation systems, guiding devices, auxiliary instruments, and cutter instruments. The handheld instruments segment accounted for the largest share of the minimally invasive surgical instruments market.
• The applications included in this report are cardiothoracic surgery, cosmetic surgery/bariatric surgery, gastrointestinal surgery, orthopedic surgery, gynaecological surgery, vascular surgery, urological surgery, and others. The others segment includes ENT/respiratory surgery, neurological surgery, dental surgery, and pediatric surgery.
• End users included in this report are government hospitals, private hospitals and surgical clinics, and medical colleges. In 2015, the private hospitals and surgical clinics segment accounted for the largest share of the global minimally invasive surgical instruments market.

Geographical Overview -
The geographic segments included in this report are North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is further segmented into the U.S. and Canada. In 2015, North America accounted for the largest share of the global minimally invasive surgical instruments market primarily due to the rising number of surgical procedures, growing government investments, growing geriatric population, and rising prevalence of lifestyle diseases in this region. With the rising geriatric population, presence of a large patient pool undergoing surgical treatments, growing awareness about modern surgical instruments and techniques, and implementation of various initiatives to reduce the rising healthcare expenditure in Asia-Pacific, the demand for minimally invasive surgical instruments in this region is expected to grow, which in turn will compel the key players to expand their geographical presence in this region.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=682

Leading Market Players -
Major players in the global minimally invasive surgical instruments market are Medtronic plc (Ireland), Ethicon, Inc. (U.S.), Aesculap, Inc. (Germany), Stryker Corporation (U.S.), and Smith & Nephew (U.K.). These players have a strong presence in major as well as emerging markets. Other players in this market are ConMed Corporation (U.S.), Abbott Laboratories (U.S.), Applied Biomedical Resources Corporation (U.S.), Microline Surgical (Japan), and Zimmer Biomet (U.S.).

Structural Heart Devices Market Leading Players and Business Strategies

According to research report the global structural heart devices market is projected to reach USD 15.08 billion by 2023 from USD 9.28 billion in 2018, at a CAGR of 10.2%. Growth in the structural heart devices market is mainly driven by factors such as the rising prevalence of structural heart diseases, regulatory approvals for new and advanced structural heart devices, favourable reimbursement scenario for structural heart procedures & devices, and increasing awareness about structural heart diseases.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=161123753

Players in this market compete to deliver superior and advanced technologies for heart valve repair and replacement. In 2017, the structural heart devices market was dominated by a few large players, namely, Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), and LivaNova plc (UK).

Edwards Lifesciences held the leading position in the global structural heart devices market in 2017 on account of its diverse portfolio of transcatheter and surgical heart valves. The company pursues organic as well as inorganic growth strategies, such as product launches & approvals and acquisitions to further increase its market share and strengthen its foothold in the surgical heart devices market. For instance, in December 2017, the company acquired Harpoon Medical Inc. (US). The unique beating-heart repair procedure for mitral valve patients of Harpoon Medical complements Edwards’ comprehensive portfolio of treatments for structural heart disease and reinforce its commitment to innovation in cardiac surgery. This acquisition was valued at USD 100 million.

Medtronic held the second position in the structural heart devices market in 2017. The company offers a comprehensive range of transcatheter and surgical heart valve products through its Coronary & Structural Heart division. The key percutaneous surgical products offered by the company include the third generation CoreValve Evolut PRO system and tissue & mechanical heart valves. To maintain its leading position in the market and increase its customer base, the company focuses on product launches & approvals, partnerships, and expansions. For instance, in 2016, the company partnered with the World Stroke Organization (WSO, Switzerland). Under this partnership, the two organizations will work together to educate, raise awareness, and support the effective management of patients who suffer from strokes.

Some of the other players operating in this market are CryoLife, Inc. (US), Micro Interventional Devices, Inc. (US), Braile Biomédica (Brazil), Lepu Medical Technology (Beijing) Co., Ltd. (China), and TTK Healthcare Limited (India).

Product launches & approvals; acquisitions; expansions; and partnerships & agreements were the key strategies adopted by key players between 2015 and 2018. Some of the key players that adopted these strategies are Edwards Lifesciences (US), Medtronic (Ireland), Boston Scientific (US), Abbott (US), LivaNova (UK), Micro Interventional Devices (US), Braile Biomédica (Brazil), and CryoLife (US).

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=161123753

Geographically, North America is expected to account for the largest share of the structural heart devices market in 2018, followed by Europe. The large share of North America in the global market is attributed to factors such as the rising prevalence of structural heart diseases, favourable reimbursement scenario for structural heart procedures and devices, technological advancements, and development of innovative devices.

Operating Room Integration Market Leading Players and Business Strategies

According to a new market research report Operating Room Integration Market is projected to grow at a CAGR of 12.4% during the forecast period, to reach USD 1.7 billion by 2024 from USD 1.0 billion in 2019.

The growth in this market is driven by the increasing adoption of minimally invasive surgical procedures, redevelopment projects & funding for improving OR infrastructure, and rising need to curtail healthcare costs. Also, emerging economies (such as China, India, Brazil, and Mexico) are expected to offer lucrative growth opportunities for market players during the forecast period.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=160774667

The RoW region is expected to witness the highest growth in the operating room integration market during the forecast period. The major factors driving the growth of this market include the procedural benefits of integrated ORs, growing prevalence of chronic diseases, and rising adoption of advanced surgical treatment methodologies in the region. Other factors augmenting market growth in this region are the ongoing expansion of the healthcare infrastructure as well as growing market availability of advanced surgical technologies in Brazil and other Latin American countries, ongoing initiatives of governments to enhance their respective healthcare systems and growing public-private investments for purchasing medical equipment.

Stryker Corporation (US), STERIS (US), KARL STORZ (Germany), and Olympus (Japan) are the key players operating in this market. Other prominent players in the market include Getinge (Sweden), Alvo Medical (Poland), Skytron (US), Merivaara (Finland), Brainlab (Germany), TRILUX Medical (Germany), caresyntax (US), Sony (Japan), Barco (Belgium), Arthrex (US), and Richard Wolf (Germany).

Stryker dominated the global operating room integration market in 2018. The company offers OR integration solutions through its Endoscopy division. Stryker holds a noteworthy position in the OR integration market, owing to its strong product portfolio. The company offers a full range of operating room products under the brand name—iSuite. In 2018, Stryker’s Endoscopy division recorded sales growth of 11.7%.

KARL STORZ held the second position in the operating room integration market. The company offers a wide range of endoscopic equipment for human, veterinary medicine, and industrial endoscopy. The company undertakes sales of operating room integration products through its Human Medicine business division. The company’s products are marketed through a network of 50 subsidiaries in over 40 countries across Europe, the Americas, Africa, and the Asia Pacific. With over 65 years of experience in this market, the company focuses on strengthening its sales activities and distribution network by working with an efficient network of dealers. The company also provides local-level services to its customers through its subsidiaries.

Get Report Sample @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=160774667

Olympus is a prominent and well-established player in the operating room integration market. The Medical Business of the company showed an increase in year-over-year net sales of 2.9% in 2018 over 2017. The company invests a significant amount of its revenue in research and development, which helps it launch technologically advanced products in the market. From 2017 to 2018, Olympus increased its Medical Business R&D expenditure by 10.7%.

Digital PCR Market - Growth Strategy Adopted Top Market Players | Industry Report 2024

According to research report the digital PCR market is projected to reach USD 6.3 billion by 2024 from USD 4.1 billion in 2019, at a CAGR of 8.8% from 2019 to 2024. The rising incidences of infectious diseases (such as HIV, tuberculosis, and malaria) and genetic disorders; continuous technological advancements in PCR technologies and the commercialization of lab-on-chip devices and microfluidics-based portable instruments; increasing investments, funds, and grants for genomic research; increasing use of biomarker profiling for disease diagnostics; and the successful completion of the Human Genome Project are expected to augment the growth of the global Digital PCR Market over the forecast period. On the other hand, the high instrument costs—especially that of dPCR—and the technical limitations of PCR are expected to limit market growth to a certain extent.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204

The major players operating in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), Takara Bio, Inc. (Japan), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US), Fluidigm Corporation (US), bioMérieux S.A. (France), Danaher Corporation (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Eppendorf AG (Germany), Promega Corporation (US), and Analytik Jena AG (Germany).

An analysis of the market developments between 2016 and 2019 revealed that several growth strategies such as product launches; partnerships and collaborations; acquisitions; and expansions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the Digital PCR Market.

Thermo Fisher Scientific (US) is one of the leading players in the field of healthcare and life science research. The company possesses a robust product portfolio in the dPCR and qPCR segment and a strong market presence globally, with sales and distribution networks in more than 50 countries. It focuses on strengthening its market position in the Digital PCR Market through product launches, acquisitions, and partnerships. The company mainly focuses on business strategies that include launching new products and gaining approvals in order to expand its product portfolio and offer customers a wide range of dPCR and qPCR products. Thermo Fisher Scientific also launched several products, including real-time PCR assay and system. It has received regulatory approvals for several other clinical assays from respective authorities. Thermo Fisher Scientific also focuses on acquisitions as a key strategy to strengthen its market position and expand its product portfolio with advanced technology products. In 2016, the company acquired Affymetrix, Inc., (US) which enabled Thermo Fisher to leverage Affymetrix’s microarray technology for novel product development.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204

Bio-Rad Laboratories (US) is one of the leading players in the field of disease diagnostics & laboratory products. The company has a noteworthy presence in the dPCR and qPCR industry and a wide geographic presence in major markets such as the US, Germany, Japan, China, India, and Brazil. Bio-Rad is involved in the development, manufacturing, and marketing of more than 5,000 reagents, apparatuses, and laboratory instruments (including qPCR and dPCR products). The acquisition of RainDance Technologies in January 2017 enabled Bio-Rad to strengthen its position in the dPCR market by leveraging RainDance’s droplet microfluid technology for novel product development and product portfolio expansion. During 2015–2018, Bio-Rad Laboratories witnessed a steady rise in the profit margin & annual revenue of its Life Sciences segment through the commercialization of its dPCR and qPCR instruments, assays, and software. In the last three years, Bio-Rad has also launched several dPCR and real-time PCR (qPCR) products to meet the growing market demand for novel clinical diagnosis products by offering innovative products to its customers from the research and clinical field.